SCHEMBL30755397

SCHEMBL30755397

Cc1cccc(C2CCC(C(F)(F)F)CC2)c1-c1ccccc1C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 1/20 0.39
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ NR1I2 O75469 1/20 0.33
▸ PGR P06401 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ TBXAS1 P24557 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ OPRK1 P41145 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ TERT O14746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27373688 1.00 MYC (0.39) MYCMEN1KMT2AATMTRPV1
SCHEMBL30755424 0.86 HSD11B1 (0.32) MEN1KMT2AATMSLC6A2TERT
SCHEMBL27373685 0.85 MYC (0.56) MYCKMT2ATRPV1LMNACYP3A4
SCHEMBL32670164 0.85 MYC (0.56) MYCKMT2ATRPV1LMNACYP3A4
SCHEMBL27372125 0.81 HTR2C (0.36) MEN1KMT2AATMTRPV1LMNA
SCHEMBL27373686 0.77 KDM4E (0.32) PDK2HSD11B1
SCHEMBL30755563 0.75 ALDH1A1 (0.37) TRPV1PDK2HSD11B1TSHRHTR2C
SCHEMBL27373684 0.75 ALDH1A1 (0.37) TRPV1PDK2HSD11B1TSHRHTR2C
SCHEMBL28327206 0.75 ADRA1A (0.40) MEN1KMT2AATMRBP4
SCHEMBL30755464 0.73 TSHR (0.37) CYP2C9CYP2C19PDK2TSHRHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
EP-4562016-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 — — EP disclosed
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK1, CDK20 MYC 468/4885MEN1 3868/4885KMT2A 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback